UK Markets closed

NVO Jan 2024 55.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
2.05000.0000 (0.00%)
At close: 10:19AM EDT
Full screen
Loading interactive chart…
  • Globe Newswire

    More people with type 2 diabetes achieved blood sugar target with once-weekly insulin icodec compared with once-daily insulin degludec

    Data presented today show more participants achieved greater treatment satisfaction when switching to once-weekly insulin icodec in ONWARDS 2 trial Bagsværd, Denmark, Thursday 22 September 2022 – Novo Nordisk today presented new data from the phase 3a ONWARDS 2 trial, demonstrating that 37% of adults with type 2 diabetes treated with once-weekly insulin icodec achieved an HbA1c <7.0%, without experiencing severe or clinically significant hypoglycaemia, compared with 27% of those treated with ins

  • Zacks

    SNY vs. NVO: Which Stock Should Value Investors Buy Now?

    SNY vs. NVO: Which Stock Is the Better Value Option?

  • Globe Newswire

    Novo Nordisk A/S – Share repurchase programme

    Bagsværd, Denmark, 19 September 2022 – On 3 August 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. Under the programme